Table 2

Demographic, laboratory and clinical summary of HIV-2 infected children on antiretroviral therapy
Patient Sex Age at diagnosis (years) Parents status Age at start of ART (years) Baseline CD4+count (%CD4) Baseline Viral load (log10copies/ml) Remarks
1 F 11 Both parents alive; HIV status unknown 12 40 (1%) Nil WHO stage 4 at start of ART Clinical follow-up for 2 months No follow-up laboratory data; Died
2 M 8 Mother dead (HIV-2 positive), Father alive (HIV-negative) 14 280 (27%) 4.5 WHO stage 4 at start of ART Clinical follow-up for 38 months Sub-optimal CD4 recovery; >0.5 log10 increase in viral load at 12 weeks; did not achieve virologic suppression throughout follow-up; LTFU
4 F 2 Both parents HIV-2 positive and alive (both on ART) 4 570 (13%) 4.6 WHO stage 3 at start of ART Clinical follow-up for 10 months No CD4 cell gain; ART discontinued at 29 weeks due to poor adherence; No follow-up viral load data; LTFU
5 M 6 Mother dead, father unknown; both parents HIV status unknown 6 140 (4%) 3.1 WHO stage 3 at start of ART Clinical follow-up for 4 months No follow-up laboratory data; Died
6 M 12 Mother dead, father unknown; both parents HIV status unknown 12 110 (8%) 4.9 WHO stage 2 at start of ART Clinical follow-up for 3 months Achieved an increase in CD4 count of 50 cells/mm3 but a 1.0 log10 increase in viral load at 12 weeks; LTFU

NOTE. LTFU = Lost to follow-up; EPTB = Extra pulmonary tuberculosis; PTB = Pulmonary tuberculosis.

Okomo et al.

Okomo et al. BMC Pediatrics 2012 12:95   doi:10.1186/1471-2431-12-95

Open Data